undamentalytics Newsletter
Sign in

Roivant Sciences Ltd. balance sheet

At the end of fiscal 2026, Roivant Sciences Ltd. had total assets of $5.71bn, total liabilities of $416m and shareholders' equity of $4.53bn. It held $1.42bn in cash against $0 of debt: net cash of $1.42bn.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Cash and equivalents2,0552,0601,6776,4952,7151,4191,248
Receivables114304———
Inventory—0335———
Total current assets2,1872,1471,7996,7325,0005,1674,742
Total assets2,5902,5852,3907,2225,4375,7095,306
Accounts payable21353814241825
Deferred revenue (current)6101241——
Total current liabilities219184272267149281284
Short-term debt004112———
Long-term debt170210376431———
Total debt170210376431—00
Total liabilities528524782774250416385
Shareholders' equity1,7981,6571,1585,9694,6884,5274,231
Non-controlling interests and other (assets − liabilities − equity)264404450480500765691
Net debt (negative = net cash)−1,885−1,850−1,301−6,064−2,715−1,419−1,248
Shares outstanding652m695m760m807m696m720m723m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EVAX vs ROIVADAG vs ROIVROIV vs TCRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Roivant Sciences Ltd.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Roivant Sciences Ltd.